The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients

Bone Marrow Transplantation

Volumn 45, Issue 7, 2010, Pages 1212-1219

  Buyck, H C ^a,b   Prentice, H G F ^b   Griffiths, P D ^a   Emery, V C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AMPHOTERICIN; CD34 ANTIGEN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CAMPATH 1G; PENTAMIDINE; UNCLASSIFIED DRUG; VALACICLOVIR; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW SUPPRESSION; CHILD; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; CYTOMEGALOVIRUS DNAEMIA; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; EX VIVO STUDY; FATALITY; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEPATITIS; HERPES SIMPLEX; HUMAN; IN VIVO STUDY; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; CYTOMEGALOVIRUS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IN VITRO STUDY; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK; RISK FACTOR; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; TIME FACTORS; YOUNG ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; IN VITRO TECHNIQUES;

EID: 77955013785     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.329     Document Type: Article

References (37)

1. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
2. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
3. Gerna G, Lilleri D, Caldera D, Furione M, Zenone Bragotti L, Alessandrino EP. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2008; 41: 873-879.
4. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy. Rev Med Virol 2006; 16: 281-287.
5. Avetisyan G, Larsson K, Aschan J, Nilsson C, Hassan M, Ljungman P. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 687-692.
6. Morita-Hoshi Y, Heike Y, Kawakami M, Sugita T, Miura O, Kim SW et al. Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 515-521.
7. Widmann T, Sester U, Gartner BC, Schubert J, Pfreundschuh M, Kohler H et al. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS ONE 2008; 3: e3634.
8. Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 2008; 93: 248-256.
9. Peggs KS, Preiser W, Kottaridis PD, McKeag N, Brink NS, Tedder RS et al. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br J Haematol 2000; 111: 782-790.
10. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003; 101: 407-414.
11. Nakamae H, Kirby KA, Sandmaier BM, Norasatthada L, Maloney DG, Maris MB et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009; 15: 694-703.
12. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873-882.
13. Waldmann H, Polliak A, Hale G, Or R, Cividalli G, Weiss L et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; 2: 483-486.
14. Bunjes D. T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983-1999. Transfus Sci 2000; 23: 151-162.
15. Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998; 92: 4581-4590.
16. Willemze R, Richel DJ, Falkenburg JH, Hale G, Waldmann H, Zwaan FE et al. In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation. Bone Marrow Transplant 1992; 9: 255-261.
17. Williams RJ, Clarke E, Blair A, Evely R, Hale G, Waldmann H et al. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH- 1H) in BM and PSBC collections; comparison with CAMPATH- 1M and CAMPATH-1G. Cytotherapy 2000; 2: 5-14.
18. Phillips J, Drumm A, Harrison P, Bird P, Bhamra K, Berrie E et al. Manufacture and quality control of CAMPATH-1 antibodies for clinical trials. Cytotherapy 2001; 3: 233-242.
19. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
20. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978-1985. (Pubitemid 34525478)
21. Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG+/-Ida) and second allogeneic stem cell transplant. Br J Haematol 2001; 115: 622-629.
22. Dreger P, Viehmann K, Steinmann J, Eckstein V, Muller- Ruchholtz W, Loffler H et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1. Exp Hematol 1995; 23: 147-154.
23. Kidd IM, Fox JC, Pillay D, Charman H, Griffiths PD, Emery VC. Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation 1993; 56: 867-871.
24. Mattes FM, Hainsworth EG, Geretti AM, Nebbia G, Prentice G, Potter M, Burroughs AK et al. A randomised control trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 2004; 189: 1355-1361.
25. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
26. Cox DR. Regression models and life tables (with discussion). J R Stat B 1972; 34: 187-220.
27. Ljungman P, Griffiths PD, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
28. Grob JP, Grundy JE, Prentice HG, Griffiths PD, Hoffbrand AV, Hughes MD et al. Immune donors can protect marrowtransplant recipients from severe cytomegalovirus infections. Lancet 1987; 1: 774-776.
29. Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102: 404-406.
30. Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 2001; 3: 261-267.
31. Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002; 99: 2586-2591.
32. Chakrabarti S, MacDonald D, Hale G, Holder K, Turner V, Czarnecka H et al. T-cell depletion with Campath-1H 'in the bag' for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 2003; 121: 109-118.
33. Novitzky N, Thomas V, Hale G, Waldmann H. Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience. Cytotherapy 2004; 6: 172-181.
34. Yanada M, Yamamoto K, Emi N, Naoe T, Suzuki R, Taji H et al. Cytomegalovirus antigenemia and outcome of patients treated with pre-emptive ganciclovir: retrospective analysis of 241 consecutive patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32: 801-807.
35. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997; 91: 119-126.
36. Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L et al. Infectious complications following allogeneic HLAidentical sibling transplantation with antithymocyte globulinbased reduced intensity preparative regimen. Leukemia 2003; 17: 2168-2177. (Pubitemid 37428382)
37. Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003; 102: 3060-3067.